STI-1492 / Sorrento - LARVOL DELTA

SOR-CART-MM-001 Study: A Phase I, Open-Label, Dose-Escalation, Pharmacokinetic, and Pharmacodynamic Study of Safety and Efficacy of CAR2 Anti-CD38 A2 CAR-T Cells in Patients with Relapsed or Refractory Multiple Myeloma (RRMM) (ASH 2023) - P1b | "A single dose of CAR2 Anti-CD38 CAR-T cells was administered 2 days post lymphodepletion with single-agent cyclophosphamide 1. This phase I trial demonstrated that CAR2 anti-CD38 A2 CAR-T cells were generally well tolerated at the Cohort 2 (MTD) dose and demonstrated objective though short responses even in patients progressing after daratumumab and belantamab mafodotin. More clinical studies are needed to optimize the efficacy and tolerability of CAR-T cell therapies for patients with RRMM. This study was completed, and no more patients will be enrolled."

CAR T-Cell Therapy • Clinical • PK/PD data • Hematological Disorders • Hematological Malignancies • Infectious Disease • Multiple Myeloma • Novel Coronavirus Disease • Oncology • Septic Shock

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1b | N=54 | Recruiting | Sponsor: Sorrento Therapeutics, Inc. | Trial completion date: Dec 2024 ➔ Feb 2026 | Trial primary completion date: Dec 2024 ➔ Dec 2025

Trial completion date • Trial primary completion date • Hematological Malignancies • Multiple Myeloma • Oncology • CD38

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1b | N=54 | Recruiting | Sponsor: Sorrento Therapeutics, Inc. | Not yet recruiting ➔ Recruiting | Initiation date: Mar 2022 ➔ Jul 2022

Enrollment open • Trial initiation date • Hematological Malignancies • Multiple Myeloma • Oncology • CD38

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1b | N=54 | Not yet recruiting | Sponsor: Sorrento Therapeutics, Inc. | Initiation date: Nov 2021 ➔ Mar 2022

Trial initiation date • Hematological Malignancies • Multiple Myeloma • Oncology • CD38

Dr. Henry Ji, Sorrento Chairman and CEO, to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021 (GlobeNewswire) - “Sorrento Therapeutics...announced today that Dr. Henry Ji, Chairman and CEO, will participate in the H.C. Wainwright 23rd Global Investment Conference...The conference is being held virtually on September 13-15, 2021…Abivertinib: Phase 3 topline data in NSCLC available Q4 2021…IND for Phase 2 in Prostate Cancer to be filed Q4 2021. PD-L1 antibody: In Phase 3 for SCLC and NDA submission in China for recurrent or metastatic cervical cancer. CD38 ADC: In Phase 1 for Amyloidosis and Multiple Myeloma. CD38 DAR-T: In Phase 1 for Relapsed and Refractory Multiple Myeloma. CD47 antibody: In Phase 1 in solid tumors. SOFUSA: Lymphatic delivery of Enbrel in Phase 1b in refractory rheumatoid arthritis patients.”

Clinical data • IND • P3 data: top line • Cervical Cancer • Genito-urinary Cancer • Gynecologic Cancers • Hematological Malignancies • Lung Cancer • Multiple Myeloma • Non Small Cell Lung Cancer • Oncology • Prostate Cancer • Small Cell Lung Cancer • Solid Tumor

Sorrento Receives FDA Authorization to Start Phase 1 Clinical Trial of Proprietary, “Off-the-Shelf“, Allogeneic anti-CD38 DAR-T (Dimeric Antigen Receptor-T) Cell Therapy to Treat Relapsed or Refractory Multiple Myeloma (GlobeNewswire) - "Sorrento Therapeutics, Inc...announced that the FDA has authorized Sorrento’s IND application for the Phase 1 clinical testing of its allogeneic anti-CD38 Dimeric Antigen Receptor (DAR) - T Cell therapy for relapsed or refractory multiple myeloma."

IND • Hematological Malignancies • Multiple Myeloma • Oncology

Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma (clinicaltrials.gov) - P1b; N=54; Not yet recruiting; Sponsor: Sorrento Therapeutics, Inc.

New P1 trial • Hematological Malignancies • Multiple Myeloma • Oncology • CD38